Innovent Biologics
2000 Alameda De Las Pulgas, Suite 120
San Mateo
CA
94403
United States
Tel: 6504551243
Website: http://innoventbio.com/en/#/
22 articles with Innovent Biologics
-
Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group
10/15/2020
Innovent Biologics, Inc. announces the appointment of Dr. Yong Jun Liu, a renowned world class scientist and successful leader in biopharmaceutical industry, as the president of the group.
-
Innovent and Lilly expect Halpryza to be a high quality and slightly more affordable rituximab injection for a market experiencing serious needs.
-
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China
10/9/2020
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY),
-
Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period
10/6/2020
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
-
TYVYT® in Combination with BYVASDA® ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (
9/28/2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced the results of a Phase 3, open label, randomized study in China.
-
Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th
9/28/2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that it will host an online virtual R&D day to mainly discuss the Company's pipeline and research.
-
Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020
9/21/2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, jointly announce with Eli Lilly and Company that biomarker results from the ORIENT-11 study were released in a mini oral presentation at the European Society for Medical Oncology Virtual Congress 2020.
-
Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
9/14/2020
Innovent Biologics, Inc. and Eli Lilly and Company jointly announce that results of six clinical studies of TYVYT® will be presented during the upcoming European Society of Medical Oncology Virtual Congress 2020 from September 19th to 21st.
-
Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China
9/3/2020
Innovent Biologics, Inc. announced that SULINNO®, a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration of China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in China.
-
Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the European Society of Cardiology Annual Conference
8/31/2020
Innovent Biologics, Inc. announced that the Phase 1 and Phase 2 clinical study results of the recombinant fully human monoclonal antibody Tafolecimab were successfully presented in the 2020 European Society of Cardiology annual conference as e-Poster.
-
Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody
8/31/2020
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announced that the Phase I clinical study (CIBI112A101) of recombinant anti-interleukin 23p19 subunit antibody injection (IBI112) has completed the first healthy subject dosing in China.
-
Innovent Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Progress
8/26/2020
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced its financial results for the six months ended June 30, 2020 and the corporate progress.
-
Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement
8/18/2020
Eli Lilly and Company and Innovent Biologics, Inc. announced a global expansion of their strategic alliance for TYVYT®, an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China.
-
Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement
8/18/2020
Innovent Biologics, Inc. and Eli Lilly and Company announced an expansion of their strategic alliance for TYVYT®, an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China.
-
Eli Lilly will aim a checkpoint inhibitor it co-developed for the Chinese market at the United States and other western markets.
-
Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China
7/8/2020
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced that the first patient has been successfully dosed in a Phase 1b clinical trial (CIBI391A101) of TYVYT®
-
Michael Yu, chairman and chief executive officer of Innovent Biologics, said the deal with Roche will help the company continue to move forward in the cellular therapy space.
-
Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies
6/8/2020
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a strategic research and development collaboration with Roche covering multiple cell therapies and bispecific antibodies.
-
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
6/2/2020
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the preliminary results of a Phase 1 clinical study (NCT03545971) of the recombinant fully human anti-cytotoxic T-lymphocyte-associated antigen 4
-
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
6/1/2020
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the preliminary results of the Phase 1a clinical study